# US 2013/0259806 A1 · Dimeric molecular complexes with free cysteine residues and conjugates thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0259806 A1
- Document ID: US20130259806A1
- Status: Published application
- Kind: A1
- Application number: 13/988,133
- Filed: 2011-12-07
- Published: 2013-10-03
- Earliest claimed: 2010-12-09
- Inventors: David Light; Paul Szymanski; Marian Seto; Aline Cornelius
- Web page: https://patentgrep.com/patent/US20130259806A1

## CPC

- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61P 35/00: Antineoplastic agents
- C07K 16/18: against material from animals or humans
- C07K 2317/528: CH4 domain
- C07K 2317/53: Hinge
- C07K 2317/55: Fab or Fab'
- C07K 2317/60: characterized by non-natural combinations of immunoglobulin fragments
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/00: Fusion polypeptide
- C07K 2319/01: containing a localisation/targetting motif
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates generally to dimeric molecular complexes comprising two fusion proteins. Each fusion protein comprises a biological effector moiety, a polypeptide spacer sequence, and an IgE CH4 dimerization domain. The dimeric molecular complexes may be conjugated, at a defined site, to other molecules including drug moieties, cytotoxic agents, labels (such as detectable labels), or biocompatible polymers.

## Claims

### Claim 1

A dimeric molecular complex comprising a first and a second fusion protein, wherein each fusion protein comprises from its N to C terminus:
(A) a biological effector moiety selected from the group consisting of:
(1) a single chain antibody;
(2) an Fab fragment;
(3) an extracellular domain of a type I membrane receptor;
(4) a cytokine;
(5) a chemokine;
(6) an enzyme; and
(7) a toxin; wherein at least one of the fusion proteins has a biological effector moiety that is a targeting biological effector moiety selected from the group consisting of (1) a single chain antibody; (2) an Fab fragment; (3) an extracellular domain of a type I membrane receptor; (4) a cytokine; (5) a chemokine; and (6) an enzyme;
(B) a polypeptide spacer sequence; and
(C) a CH4 dimerization domain of an IgE molecule covalently bound to the polypeptide spacer sequence;
wherein the molecular complex comprises at least one disulfide bond between a cysteine residue in the first fusion protein and a cysteine residue in the second fusion protein, and at least one of the fusion proteins comprises one or more free cysteine amino acid residues.

### Claim 2 (depends on 1)

The molecular complex of claim 1, wherein the biological effector moieties of the first and second fusion proteins each comprises an antigen binding site.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The molecular complex of claim 1, wherein i) cysteine residue in the biological effector moiety is replaced with a non-cysteine residue to create a free cysteine residue, or ii) a non-cysteine residue in the CH4 dimerization domain is replaced with a cysteine residue to create a free cysteine residue.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The molecular complex of claim 1, wherein i) the CH4 dimerization domain comprises the amino acid sequence of SEQ ID NO: 28, or ii) the CH4 dimerization domain comprises an amino acid sequence of SEQ ID NO: 28 that is mutated such that a non-cysteine residue at position Ala4, Val146, Ala51, Ala77, Lys82, Ser95, Gln101, Ala103 or Ser105 is replaced with a cysteine residue.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The molecular complex of claim 1, wherein the first and the second fusion protein each further comprises an M2″ extension of an IgE splice variant located between the CH4 dimerization domain and the C-terminus of the protein.

### Claim 10 (depends on 1)

The molecular complex of claim 1, wherein the polypeptide spacer sequences of both the first and second fusion protein each comprises an IgG hinge.

### Claim 11

(canceled)

### Claim 12 (depends on 10)

The molecular complex of claim 10, wherein the hinge region of at least one of the first and the second fusion protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, and SEQ ID NO: 59.

### Claim 13 (depends on 1)

The molecular complex of claim 1, wherein the polypeptide spacer sequences of both the first and the second fusion proteins each comprises 10-500 amino acids, and wherein each of the polypeptide spacer sequences is covalently bound to the biological effector moiety and the CH4 dimerization domain.

### Claim 14

A dimeric molecular complex comprising a first and a second fusion protein, wherein each fusion protein comprises from its N to C terminus:
(A) an IgE CH4 dimerization domain with a C terminal extension comprised of an M2″ extension of an IgE CH4 splice variant;
(B) an amino acid spacer which is covalently bound to the IgE CH4 dimerization domain; and
(C) an extracellular domain of a type II membrane receptor;
wherein the molecular complex comprises at least one disulfide bond between a cysteine residue in the first fusion protein and a cysteine residue in the second fusion protein, and at least one of the fusion proteins comprises one or more free cysteine amino acid residues.

### Claim 15

A nucleic acid molecule which encodes a fusion protein comprising from N to C terminus:
(A) a biological effector moiety selected from the group consisting of:
(1) a single chain antibody;
(2) an Fab fragment;
(3) an extracellular domain of a type I membrane receptor;
(4) a cytokine;
(5) a chemokine;
(6) an enzyme; and
(7) a toxin;
(B) a polypeptide spacer sequence; and
(C) a CH4 dimerization domain of an IgE molecule covalently bound to the polypeptide spacer sequence;
wherein the fusion protein comprises one or more free cysteine amino acid residues.

### Claim 16 (depends on 15)

The nucleic acid molecule of claim 15, wherein the biological effector moiety comprises an antigen binding site.

### Claim 17 (depends on 15)

The nucleic acid molecule of claim 15, wherein a non-cysteine residue in the CH4 dimerization domain is replaced with a cysteine residue to create the free cysteine residue.

### Claim 18 (depends on 15)

The nucleic acid molecule of claim 15, wherein i) the CH4 dimerization domain comprises the amino acid sequence of SEQ ID NO: 28, or ii) the CH4 dimerization domain comprises an amino acid sequence of SEQ ID NO: 28 that is mutated such that a non-cysteine residue at position Ala4, Val46, Ala51, Ala77, Lys82, Ser95, Gln101, Ala103 or Ser105 is replaced with a cysteine residue.

### Claim 19

(canceled)

### Claim 20 (depends on 15)

The nucleic acid molecule of claim 15, wherein the fusion protein further comprises an M2″ extension of an IgE splice variant located between the CH4 dimerization domain and the C-terminus of the protein.

### Claim 21 (depends on 15)

The nucleic acid molecule of claim 15, wherein the polypeptide spacer sequence comprises an IgG hinge.

### Claim 22

(canceled)

### Claim 23 (depends on 21)

The nucleic acid molecule of claim 21, wherein the hinge region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, and SEQ ID NO: 59.

### Claim 24 (depends on 15)

The nucleic acid molecule of claim 15, wherein the polypeptide spacer sequence comprises 1-200 amino acids, and is covalently bound to the biological effector moiety and the CH4 dimerization domain.

### Claim 25 (depends on 15)

An expression cassette comprising the nucleic acid molecule of claim 15.

### Claim 26 (depends on 15)

A host cell comprising the nucleic acid molecule of claim 15.

### Claim 27

A conjugate comprising a dimeric molecular complex coupled to a drug moiety, cytotoxic agent, label, or biocompatible polymer as shown in (I):
D-La-M (I)
wherein D is the dimeric molecular complex, L is a linker covalently attached to D at a free cysteine on D, M is a conjugate molecule selected from a drug moiety, cytotoxic agent, label, or biocompatible polymer, and a is 0 or 1 and further wherein the dimeric molecular complex comprises a first and a second fusion protein, wherein each fusion protein comprises from its N to C terminus:
(A) a biological effector moiety selected from the group consisting of:
(1) a single chain antibody;
(2) an Fab fragment;
(3) an extracellular domain of a type I membrane receptor;
(4) a cytokine;
(5) a chemokine;
(6) an enzyme; and
(7) a toxin; wherein at least one of the fusion proteins has a biological effector moiety that is a targeting biological effector moiety selected from the group consisting of (1) a single chain antibody; (2) an Fab fragment; (3) an extracellular domain of a type I membrane receptor; and (4) an enzyme;
(B) a polypeptide spacer sequence; and
(C) a CH4 dimerization domain of an IgE molecule covalently bound to the polypeptide spacer sequence;
wherein the molecular complex comprises at least one disulfide bond between a cysteine residue in the first fusion protein and a cysteine residue in the second fusion protein, and at least one of the fusion proteins comprises one or more free cysteine amino acid residues that reacts with the linker to form the conjugate or, if a is 0, reacts with the conjugate molecule to form the conjugate.

### Claim 28 (depends on 27)

The conjugate of claim 27, wherein at least one of the biological effector moieties of the first and second fusion proteins comprises an antigen binding site.

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31 (depends on 27)

The conjugate of claim 27, wherein M is a cytotoxic agent and the biological effector moiety comprises an antigen binding site for a cancerous cell.

### Claim 32 (depends on 27)

The conjugate of claim 27, wherein M is a drug moiety and the biological effector moiety targets a diseased tissue.

### Claim 33 (depends on 27)

The conjugate of claim 27, wherein a non-cysteine residue in the CH4 dimerization domain of the first or second fusion protein is replaced with a cysteine residue to create the free cysteine residue.

### Claim 34 (depends on 27)

The conjugate of claim 27, wherein i) the CH4 dimerization domain of the first or second fusion protein comprises the amino acid sequence of SEQ ID NO: 28, or ii) the CH4 dimerization domain of the first or second fusion protein comprises an amino acid sequence of SEQ ID NO: 28 that is mutated such that a non-cysteine residue at position Ala4, Val46, Ala51, Ala77, Lys82, Ser95, Gln101, Ala103 or Ser105 is replaced with a cysteine residue that is the site of attachment to the linker.

### Claim 35

(canceled)

### Claim 36 (depends on 27)

The conjugate of claim 27, wherein the first and the second fusion protein each further comprises an M2″ extension of an IgE splice variant located between the CH4 dimerization domain and the C-terminus of the protein.

### Claim 37 (depends on 27)

The conjugate of claim 27, wherein the polypeptide spacer sequences of both the first and second fusion protein each comprises an IgG hinge.

### Claim 38

(canceled)

### Claim 39 (depends on 37)

The conjugate of claim 37, wherein the hinge region of at least one of the first and the second fusion protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, and SEQ ID NO: 59.

### Claim 40 (depends on 27)

The conjugate of claim 27, wherein the polypeptide spacer sequences of both the first and the second fusion proteins each comprises 1-200 amino acids, and each is covalently bound to the biological effector moiety and the CH4 dimerization domain.

### Claim 41 (depends on 27)

A pharmaceutical composition comprising the conjugate of claim 27 and a pharmaceutically acceptable excipient.

### Claim 42 (depends on 27)

A method of killing or inhibiting the proliferation of tumor cells or cancer cells comprising administering to a patient in need thereof an effective amount of the conjugate of claim 27, wherein the dimeric molecular complex of the conjugate has at least one biological effector moiety that comprises an antigen binding site for a tumor-associated antigen and M is a cytotoxic agent or a drug that is a chemotherapeutic agent.

### Claim 43 (depends on 27)

A method of imaging a target area of a body in a patient in need thereof comprising administering to a patient a conjugate of claim 27 in an amount sufficient to provide a detectable signal at the target area and detecting the signal, wherein at least one of the biological effector moieties of the first and second fusion proteins targets a specific cell type or tissue in need of imaging and M of the conjugate is a detectable label.

### Claim 44 (depends on 27)

A method of making the conjugate of claim 27, comprising reacting:
(I) a dimeric complex that comprises a first and a second fusion protein, wherein each fusion protein comprises from its N to C terminus:
(A) a biological effector moiety selected from the group consisting of:
(1) a single chain antibody;
(2) an Fab fragment;
(3) an extracellular domain of a type I membrane receptor;
(4) a cytokine;
(5) a chemokine;
(6) an enzyme; and
(7) a toxin; wherein at least one of the fusion proteins has a biological effector moiety that is a targeting biological effector moiety selected from the group consisting of (1) a single chain antibody; (2) an Fab fragment; (3) an extracellular domain of a type I membrane receptor; (4) a cytokine; (5) a chemokine; and (6) an enzyme;
(B) a polypeptide spacer sequence; and
(C) a CH4 dimerization domain of an IgE molecule covalently bound to the polypeptide spacer sequence;
wherein the molecular complex comprises at least one disulfide bond between a cysteine residue in the first fusion protein and a cysteine residue in the second fusion protein, and at least one of the fusion proteins comprises one or more free cysteine amino acid residues with
(II) La-M, wherein if a is 1 then L has a functional group that reacts preferentially with the molecular complex at the free cysteine such that the conjugate is formed and if a is 0 then M has a functional group that reacts preferentially with the molecular complex at the free cysteine such that the conjugate is formed.

### Claim 45 (depends on 44)

The method of claim 44, wherein a is 1 and the linker (L) has a maleimide functional group that reacts with the free cysteine to covalently attach the dimeric molecular complex to L-M.
